Triple negative breast cancer: Pitfalls and progress
P Zagami, LA Carey - NPJ breast cancer, 2022 - nature.com
Triple negative breast cancer (TNBC) is characterized by the lack of estrogen and
progesterone receptor expression and lacks HER2 overexpression or gene amplification. It …
progesterone receptor expression and lacks HER2 overexpression or gene amplification. It …
HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
Human epidermal growth factor receptor 2 (HER2) positive breast cancer accounts for 20–
25% of all breast cancers. Multiple HER2-targeted therapies have been developed over the …
25% of all breast cancers. Multiple HER2-targeted therapies have been developed over the …
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis
Abstract The AURORA US Metastasis Project was established with the goal to identify
molecular features associated with metastasis. We assayed 55 females with metastatic …
molecular features associated with metastasis. We assayed 55 females with metastatic …
Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and …
Objective To evaluate pathological complete response as a surrogate endpoint for disease-
free survival and overall survival in regulatory neoadjuvant trials of early stage breast …
free survival and overall survival in regulatory neoadjuvant trials of early stage breast …
CALGB 40603 (Alliance): long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and …
PURPOSE CALGB 40603 (NCT00861705), a 2× 2 randomized phase II trial, demonstrated
that adding carboplatin or bevacizumab to weekly paclitaxel (wP) followed by doxorubicin …
that adding carboplatin or bevacizumab to weekly paclitaxel (wP) followed by doxorubicin …
[HTML][HTML] Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer
Background Both clinical and genomic data independently predict survival and treatment
response in early-stage HER2-positive breast cancer. Here we present the development …
response in early-stage HER2-positive breast cancer. Here we present the development …
Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual ERBB2 blockade in patients with ERBB2-positive breast …
A van der Voort, MS Van Ramshorst… - JAMA …, 2021 - jamanetwork.com
Importance Primary analysis of the TRAIN-2 study showed high pathologic complete
response rates after neoadjuvant chemotherapy with or without anthracyclines plus …
response rates after neoadjuvant chemotherapy with or without anthracyclines plus …
Breast cancer: an overview of current therapeutic strategies, challenge, and perspectives
J Wang, SG Wu - Breast Cancer: Targets and Therapy, 2023 - Taylor & Francis
Breast cancer is the most commonly diagnosed cancer and the leading cause of death
among female patients, which seriously threatens the health of women in the whole world …
among female patients, which seriously threatens the health of women in the whole world …
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer …
U Nitz, O Gluz, M Graeser, M Christgen… - The Lancet …, 2022 - thelancet.com
Background Several de-escalation neoadjuvant strategies have been investigated to reduce
the use of chemotherapy in HER2-positive early breast cancer using pathological complete …
the use of chemotherapy in HER2-positive early breast cancer using pathological complete …
The sequence of chemotherapy and toripalimab might influence the efficacy of neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell …
W **ng, L Zhao, Y Zheng, B Liu, X Liu, T Li… - Frontiers in …, 2021 - frontiersin.org
Background There is no standard neoadjuvant therapy for locally advanced esophageal
cancer in China. The role of neoadjuvant chemotherapy plus immunotherapy for locally …
cancer in China. The role of neoadjuvant chemotherapy plus immunotherapy for locally …